Trials / Unknown
UnknownNCT01461759
Efficacy Study of Chemotherapy to Treat Advanced or Recurrent Endometrial Cancer
A Phase II Trial of Docetaxel / Cisplatin in Patients With Recurrent or Stage IVb Endometrial Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 59 (estimated)
- Sponsor
- Asan Medical Center · Academic / Other
- Sex
- Female
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to treat advanced or recurrent endometrial cancer, paclitaxel-containing regimen is the preferred chemotherapeutic regimen which is selected by most physicians. Docetaxel may have similar efficacy and more favorable treatment related toxicity profile as tested in epithelial ovarian cancer trials. Therefore, the investigators aimed to evaluate the efficacy and safety of docetaxel plus cisplatin in patients with advanced or recurrent endometrial cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Doctaxel | Docetaxel 70mg/m2BSA, q 3 weeks, 8 cycles |
| DRUG | Cisplatin | Cisplatin 60mg/m2BAS, q 3 weeks, 8 cycles |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2017-12-01
- Completion
- 2017-12-01
- First posted
- 2011-10-28
- Last updated
- 2017-05-31
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01461759. Inclusion in this directory is not an endorsement.